Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx

publication date: Jun 10, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangsu Chia-tai Tianqing Pharmaceutical Co. in-licensed China rights to BL-8030, an oral treatment for hepatitis C virus, from BioLineRx, an Israeli clinical-stage pharma. CTTQ makes chemical drugs and TCM products, with liver disease a specialty for the company. BioLine will be eligible for up to $30 million in upfront and milestone payments. More details....

Stock Symbol: (NSDQ: BLRX); TASE: BLRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners